Alexion Pharmaceuticals PT Raised to $138.00 (ALXN)
Analysts at Canaccord Genuity increased their price objective on shares of Alexion Pharmaceuticals (NASDAQ:ALXN) from $132.00 to $138.00 in a research report issued to clients and investors on Friday, AmericanBankingNews.com reports. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price points to a potential upside of 10.25% from the company’s current price.
ALXN has been the subject of a number of other recent research reports. Analysts at Barclays raised their price target on shares of Alexion Pharmaceuticals from $121.00 to $127.00 in a research note to investors on Friday. They now have an “overweight” rating on the stock. Separately, analysts at Stifel Nicolaus raised their price target on shares of Alexion Pharmaceuticals from $131.00 to $138.00 in a research note to investors on Friday. They now have a “buy” rating on the stock. Finally, analysts at Zacks upgraded shares of Alexion Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note to investors on Friday, October 18th. They now have a $133.00 price target on the stock. One investment analyst has rated the stock with a sell rating, six have given a hold rating and thirteen have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $121.72.
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) traded up 7.26% during mid-day trading on Friday, hitting $125.17. The stock had a trading volume of 2,626,550 shares. Alexion Pharmaceuticals has a 1-year low of $81.82 and a 1-year high of $125.65. The stock’s 50-day moving average is $111.0 and its 200-day moving average is $100.2. The company has a market cap of $24.478 billion and a price-to-earnings ratio of 66.53.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 24th. The company reported $0.83 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.79 by $0.04. The company had revenue of $400.40 million for the quarter, compared to the consensus estimate of $395.10 million. During the same quarter in the prior year, the company posted $0.60 earnings per share. The company’s quarterly revenue was up 36.1% on a year-over-year basis. On average, analysts predict that Alexion Pharmaceuticals will post $3.04 earnings per share for the current fiscal year.
Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.